Showing 2041-2050 of 2526 results for "".
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patientshttps://modernod.com/news/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients/2478948/Alteogen announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened compet
- CooperVision Introduces 2021 Best Practices Honoreeshttps://modernod.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/During a year of unprecedented challenges brought on by the COVID-19 pandemic, eye care practices across the nation have adapted to meet the changing needs of their patients and find ways to not only survive, but thrive. In celebration of 10 such practices, CooperVision announced its 2021 Bes
- Second Sight Receives FDA Approval for the Argus 2s Retinal Prosthesis Systemhttps://modernod.com/news/second-sight-receives-fda-approval-for-the-argus-2s-retinal-prosthesis-system/2478941/Second Sight Medical Products announced FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). Th
- Eyenovia Announces FDA Acceptance of Filing of NDA for MydCombihttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/Eyenovia announced that the FDA has accepted the company’s new drug application (NDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Icahn to Push for Changes at Bausch Health After Disclosing Stakehttps://modernod.com/news/icahn-to-push-for-changes-at-bausch-health-after-disclosing-stake/2478869/Activist investor Carl Icahn disclosed in a regulatory filing that he has accumulated a 7.8% stake in Bausch Health, making him the largest single shareholder in the company. According to the filing, Icahn believes Bausch shares are “undervalued,” and that he plans to “engage in
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I